2023
DOI: 10.1016/j.yrtph.2023.105522
|View full text |Cite
|
Sign up to set email alerts
|

Carcinogenicity testing in drug development: Getting it right

Paul Baldrick,
Sanjay Jain
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 12 publications
0
1
0
Order By: Relevance
“…Carcinogenicity is a signi cant concern among the toxicological endpoints of drugs. Carcinogenic drugs can interfere with the genome or cellular metabolic processes in the human physiological system (Baldrick and Jain, 2023;Zenkov et al, 2020). Curcumin, Demethoxycurcumin, Bisdemethoxycurcumin, Cyclocurcumin were predicted to be non-carcinogenic (Table 5), attributable to their abilities to pass the in exible and thorough drug-likeness screening.…”
Section: Discussionmentioning
confidence: 99%
“…Carcinogenicity is a signi cant concern among the toxicological endpoints of drugs. Carcinogenic drugs can interfere with the genome or cellular metabolic processes in the human physiological system (Baldrick and Jain, 2023;Zenkov et al, 2020). Curcumin, Demethoxycurcumin, Bisdemethoxycurcumin, Cyclocurcumin were predicted to be non-carcinogenic (Table 5), attributable to their abilities to pass the in exible and thorough drug-likeness screening.…”
Section: Discussionmentioning
confidence: 99%